AFT Pharmaceuticals

AFT Pharmaceuticals is a specialty pharmaceutical company that operates primarily in Australasia but has product distribution agreements across the globe. The company’s product portfolio includes prescription and over-the-counter (OTC) drugs to treat a range of conditions and a proprietary nebuliser.

Equities

Equities by Sector

Sectors

Thematics

Latest

Decarbonising the built environment – Green materials, greener buildings

The advertising ecosystem – Triangulating perspectives

JPMorgan European Discovery Trust – The power of small

Audiovisual

Latest

Vantage: VOF – inside Vietnam’s investment boom (27 June 2025)

Cereno Scientific – executive interview

Partners Group Private Equity in 60 seconds

About Edison

About Edison

Careers

AFT Pharmaceuticals (NZX: AFT)

Latest Insights

AFT Pharmaceuticals — Making progress on growth strategy

AFT Pharmaceuticals — Setting the stage for sustained long-term growth

AFT Pharmaceuticals — Softer H1 on one-offs; recovery expected in H2

AFT Pharmaceuticals — H125 profitability weighed down by one-offs

Sector

Equity Analyst

Key Management

Research

AFT Pharmaceuticals — Maxigesic IV’s Brazil entry, a foray into LATAM

AFT Pharmaceuticals — Expanded R&D pipeline to fuel LT growth

AFT Pharmaceuticals — Growth underpinned by international momentum

AFT Pharmaceuticals — Poised for international market expansion

AFT Pharmaceuticals — US milestone triggers upside and guidance bump

AFT Pharmaceuticals — US maiden voyage with Maxigesic IV launch

AFT Pharmaceuticals — Another R&D asset in the bag

AFT Pharmaceuticals — R&D pipeline strengthens with new candidate

AFT Pharmaceuticals — Global growth despite tough macro environment

AFT Pharmaceuticals — FDA nod for opioid alternative, upside anticipated

AFT Pharmaceuticals — Judgment clears AFT of lump sum payment claim

AFT Pharmaceuticals — Near-term goals in sight with FY23 momentum

AFT Pharmaceuticals — Maxigesic IV closer to FDA approval

AFT Pharmaceuticals — Maxigesic international momentum continues

AFT Pharmaceuticals — Big win with Maxigesic Rapid’s FDA nod

AFT Pharmaceuticals — Portfolio expansion with new in-licensing deal

AFT Pharmaceuticals — Maxigesic IV expands into East European markets

AFT Pharmaceuticals — Progressive outlook for CY23

AFT Pharmaceuticals — H123 focused on portfolio expansion

AFT Pharmaceuticals — Further studies for Maxigesic IV’s US nod

AFT Pharmaceuticals — Collaboration for developing birthmark medicine

AFT Pharmaceuticals — Pascomer falls short of FDA mandated threshold

AFT Pharmaceuticals — Expanding reach into China

AFT Pharmaceuticals — Maxigesic IV hits a roadblock in the US

AFT Pharmaceuticals — Re-acceleration leveraging its platform

AFT Pharmaceuticals — Recovery driven by strong H222

AFT Pharmaceuticals — 14% revenue growth despite COVID-19 headwinds

AFT Pharmaceuticals — Growth in the face of a challenging environment

AFT Pharmaceuticals — Growth despite COVID-19 challenges

AFT Pharmaceuticals — Solid FY20 results

AFT Pharmaceuticals — A strong start to FY20

AFT Pharmaceuticals — A licensing deal for Pascomer

AFT Pharmaceuticals — Operating profitability achieved

AFT Pharmaceuticals — Margins improving

AFT Pharmaceuticals — Strong FY18 results

AFT Pharmaceuticals — Improving profitability

AFT Pharmaceuticals — Australia and Maxigesic driving growth

AFT Pharmaceuticals — On the cusp

AFT Pharmaceuticals — Updates on several products

AFT Pharmaceuticals — Update 5 December 2016

AFT Pharmaceuticals — Update 31 May 2016

AFT Pharmaceuticals — Update 21 December 2015